Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

Similar articles for PubMed (Select 23483980)

1.

Mechanisms of cyclic nucleotide phosphodiesterases in modulating T cell responses in murine graft-versus-host disease.

Weber M, Lupp C, Stein P, Kreft A, Bopp T, Wehler TC, Schmitt E, Schild H, Radsak MP.

PLoS One. 2013;8(3):e58110. doi: 10.1371/journal.pone.0058110. Epub 2013 Mar 6.

2.

[Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].

Cao J, Li L, Chen C, Zeng LY, Li ZY, Pan XY, Xu KL.

Zhonghua Xue Ye Xue Za Zhi. 2011 Feb;32(2):83-8. Chinese.

4.

Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.

Park MJ, Moon SJ, Lee SH, Yang EJ, Min JK, Cho SG, Yang CW, Park SH, Kim HY, Cho ML.

PLoS One. 2013 Jun 20;8(6):e67171. doi: 10.1371/journal.pone.0067171. Print 2013.

5.
6.

Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.

Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M, Abe R, Li XK.

Transplantation. 2007 Mar 27;83(6):774-82.

PMID:
17414712
7.

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Pillai AB, George TI, Dutt S, Strober S.

Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.

8.

Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.

Chen C, Cao J, Zeng L, Li Y, Wang D, Xu K.

Transplant Proc. 2011 Jun;43(5):2041-8. doi: 10.1016/j.transproceed.2011.02.055.

PMID:
21693322
9.

IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.

Koenecke C, Lee CW, Thamm K, Föhse L, Schafferus M, Mittrücker HW, Floess S, Huehn J, Ganser A, Förster R, Prinz I.

J Immunol. 2012 Sep 15;189(6):2890-6. doi: 10.4049/jimmunol.1200413. Epub 2012 Aug 6.

10.

CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.

Park HB, Oh K, Garmaa N, Seo MW, Byoun OJ, Lee HY, Lee DS.

Transplantation. 2010 Oct 27;90(8):825-35. doi: 10.1097/TP.0b013e3181f24e59.

PMID:
20697326
11.

A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Tawara I, Shlomchik WD, Jones A, Zou W, Nieves E, Liu C, Toubai T, Duran-Struuck R, Sun Y, Clouthier SG, Evers R, Lowler KP, Levy RB, Reddy P.

J Immunol. 2010 Oct 1;185(7):3866-72. doi: 10.4049/jimmunol.1001625. Epub 2010 Sep 1.

12.
13.

In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease.

Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D.

Blood. 2008 Sep 1;112(5):2129-38. doi: 10.1182/blood-2008-02-140277. Epub 2008 Jun 12.

14.

IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.

Colonna L, Florek M, Leveson-Gower DB, Sega EI, Baker J, Smith AT, Negrin RS.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1557-65. doi: 10.1016/j.bbmt.2013.07.024. Epub 2013 Aug 3.

15.

Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.

Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka K, Fujii N, Kondo E, Shinagawa K, Tanaka T, Takeuchi K, Teshima T, Tanimoto M.

Biol Blood Marrow Transplant. 2014 Feb;20(2):183-91. doi: 10.1016/j.bbmt.2013.11.018. Epub 2013 Dec 10.

16.

IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Lu Y, Giver CR, Sharma A, Li JM, Darlak KA, Owens LM, Roback JD, Galipeau J, Waller EK.

Blood. 2012 Jan 26;119(4):1075-85. doi: 10.1182/blood-2010-12-322891. Epub 2011 Nov 30.

17.

Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.

Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M.

Blood. 2006 May 1;107(9):3787-94. Epub 2006 Jan 17.

18.

Inhibition of graft-versus-host disease by double-negative regulatory T cells.

Young KJ, DuTemple B, Phillips MJ, Zhang L.

J Immunol. 2003 Jul 1;171(1):134-41.

19.

The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.

Dey B, Yang YG, Preffer F, Shimizu A, Swenson K, Dombkowski D, Sykes M.

Transplantation. 1999 Jul 15;68(1):141-9.

PMID:
10428282
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk